A phase 2 trial evaluated the efficacy and safety of BI 1358894, a novel TRPC4/5 inhibitor, in treating Borderline Personality Disorder (BPD). Despite showing safety and tolerability, the trial did not meet its primary efficacy endpoint, with no significant differences observed between treatment groups and placebo. The study highlights the challenges of high placebo responses in BPD trials and the need for novel treatment approaches.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.